Solasia Pharma K.K.
4597.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.92B
Close$
Share Statistics
| Market cap | $7.92 Billion |
|---|---|
| Enterprise Value | $6.71 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.69 |
| Beta | 1.18 |
| Outstanding Shares | 273,005,222 |
Return
| Return on Equity | -61.98% |
|---|---|
| Return on Assets | -47.44% |
| Return on Invested Capital | -58.72% |
Valuation & Multiples
| P/E Ratio | -8.71 |
|---|---|
| PEG | -254.49 |
| Price to Sales | 29.0 |
| Price to Book Ratio | 5.8 |
| Enterprise Value to Revenue | 17.28 |
| Enterprise Value to EBIT | -7.52 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Solasia Pharma K.K.
22 employees
CEO: Yoshihiro Arai Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-...